Logo of Gobroad Healthcare Group

Gobroad Healthcare Group

Top Cancer Treatment and CAR-T Cell Therapy Center in Beijing, China

No. 6 South Zhengwangfen, Fengtai District, Beijing, Building 1, No.4 Science Park Road, Life Sciences Park, Changping District, Beijing, Beijing, China
Price Range: $100000 - $100000
Specialty: Cancer Treatment, Neurology, Pediatric Treatment
Focus Area: Beijing Gobroad Boren Hospital | Beijing | China | CAR-T Cell Therapy for Cancer | Lymphoma Treatments | Leukemia Treatments | Multiple Myeloma Treatments | NK Cell Therapy for Cancer

Gobroad Healthcare Group Profile Overview

Beijing Gobroad Boren Hospital

Beijing Gobroad Boren Hospital in ChinaBeijing Gobroad Boren Hospital stands at the forefront of oncology care in Beijing, China. Renowned for its specialized approach to treating hematological malignancies, the hospital is a beacon of hope for patients battling severe forms of cancer. Our expertise spans a broad spectrum of conditions, including lymphoma, leukemia, and multiple myeloma. We take pride in our advanced CAR-T cell therapy, a revolutionary treatment for refractory and relapsed cancers, which has achieved remarkable success in both adults and children.

Our hospital boasts one of the most extensive CAR-T therapy portfolios globally, with nearly 30 CAR-T targets available, including CD7-CART, CD5-CART, and the CD19/CD22/CD20-triple target CART. Additionally, our CAR-NK and UCART therapies further enhance our capabilities.

“With over 4,000 patients treated to date, our clinical outcomes are a testament to the effectiveness of our cutting-edge therapies and the dedication of our highly skilled medical team.” - Beijing Gobroad Boren Hospital

Our Cancer Treatments Services in Beijing, China

  • CAR-T Cell Therapy for Cancer: CAR-T cell therapy is a pioneering treatment where a patient’s T cells are genetically engineered to recognize and attack cancer cells.

  • Lymphoma Treatments: We provide personalized treatment plans based on the type and stage of lymphoma, ensuring each patient receives the most effective care tailored to their specific needs.

  • Leukemia Treatments: Our treatments aim to target leukemia cells directly, minimizing side effects and improving patient outcomes.

  • Multiple Myeloma Treatments: Our hospital provides advanced therapies for multiple myeloma, including novel CAR-T cell treatments designed to target the unique characteristics of myeloma cells.

  • NK Cell Therapy for Cancer: This therapy leverages the power of NK cells to target and destroy cancer cells, provides a promising option for patients with various types of cancer.

Leading Cancer Care at Beijing Gobroad Boren Hospital in China

Gobroad Boren Hospital in Beijing ChinaAt Beijing Gobroad Boren Hospital, we pride ourselves on delivering exceptional cancer care through cutting-edge technologies and personalized treatment plans. Our commitment to cancer patients is unwavering, as we strive to offer hope and healing through the latest advancements in cancer treatment. Our state-of-the-art facilities, combined with a team of highly skilled medical professionals, ensure that each patient receives tailored care that addresses their unique needs and challenges. Our mission is to provide the best possible outcomes for our patients by harnessing the power of innovative therapies and comprehensive support. 

Why Choose Cancer Treatment in Beijing, China?

  • Proven Track Record: Our extensive experience and high success rate are testaments to the effectiveness of our therapies.

  • Expertise in CAR-T Therapy: Our hospital offers one of the most comprehensive CAR-T therapy programs globally, with nearly 30 CAR-T targets available.

  • Advanced Technology: We utilize cutting-edge technology in all aspects of our cancer treatments, from CAR-T cell therapy to NK cell therapy.

  • Personalized Care: Our multidisciplinary team works closely with each patient to develop personalized treatment plans that address their specific condition and needs.

  • Comprehensive Support: Beyond advanced medical treatments, we offer comprehensive support services to help patients through their cancer journey.

Top Oncologists at Gobroad Boren Hospital in Beijing, China

Our expert team at Beijing Gobroad Boren Hospital includes leading oncologists like Dr. Yajing Zhang in CAR-T therapy, Dr. Kai Hu in lymphoma and leukemia, Dr. Shuangyou Liu in multiple myeloma, Dr. Jing Pan in cancer immunotherapy, and Dr. Tong Wu in complex hematological cases. Their extensive experience and commitment ensure exceptional care and advanced treatment for our patients.

Dr. Yajing Zhang“Hi, my name is Dr. Yajing Zhang, and I am a leading expert in CAR-T cell therapy at Beijing Gobroad Boren Hospital. With a deep-rooted passion for oncology and years of experience in treating hematological malignancies, my role involves harnessing the latest CAR-T technologies to offer targeted and effective treatment for our patients. My specialization focuses on providing personalized care, meticulously designed to meet each patient's unique needs and circumstances. I am committed to pushing the boundaries of cancer treatment through innovative approaches, ensuring that our patients receive the highest standard of care. My dedication to advancing CAR-T therapy has significantly contributed to our hospital's reputation for excellence in cancer treatment.” - Dr. Yajing Zhang

Schedule Your Consultation Now at PlacidWay!

Ready to take the next step in your cancer treatment journey? Beijing Gobroad Boren Hospital offers world-class care and innovative therapies to help you fight cancer. Book your consultation through PlacidWay today and discover how our advanced treatments can make a difference in your battle against cancer. Our dedicated team is here to provide the support and expertise you need for a successful treatment journey.

contact us


Gobroad Healthcare Group, Beijing, China Profile Details

Our core medical technologies include CAR-T cell therapy and hematopoietic stem cell transplantation, used to treat various hematologic malignancies like lymphoma, leukemia, and multiple myeloma in both adults and children, autoimmune diseases, and solid tumors. We have successfully treated nearly 4,000 patients with CAR-T cell therapy. Our team of highly skilled doctors and nurses have achieved excellent clinical outcomes due to our broad range of nearly 30 CAR-T targets, including CD7-CART, CD5-CART, CD19/CD22/CD20-triple target CART, CAR-NK, UCART, etc., which are among the most comprehensive in the field. To date, we have published over 50 global academic papers and presented our findings at more than 100 international academic conferences.


Location